Trial Profile
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.